[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT
This First Amendment to the Development and License Agreement (the “First Amendment”) is made and
entered into effective as of October 22, 2001 (the “Effective Date”), by and between Novo Nordisk A/S, Novo
Allé DK-2880 Bagsværd, Denmark (“Novo Nordisk”), and Aradigm Corporation, 3929 Point Eden Way,
Hayward, California 94545 (“Aradigm”). Novo Nordisk and Aradigm may be referred to herein as a “Party” or,
collectively, as “Parties”.
WHEREAS, effective June 2, 1998, Novo Nordisk and Aradigm entered into a Development and License
Agreement (the “Development Agreement”) for the development and commercialization of a system for
pulmonary delivery of insulin (and potentially other related compounds);
WHEREAS, pursuant to the Development Agreement, Aradigm granted Novo Nordisk an exclusive,
worldwide license under Aradigm’s Patent Rights and Know-how, to register, use, market, distribute, sell, with
sublicense rights, and certain rights to package and produce products resulting from such development activities;
WHEREAS , the Parties desire to amend the Development Agreement to correspond with the Manufacturing
and Supply Agreement entered into between Novo Nordisk and Aradigm on October 22, 2001.
NOW THEREFORE , the Parties agree as follows:
1. Amendment of the Development Agreement .
The Parties hereby agree to amend the terms of the Development Agreement as provided below. To the extent
that the Development Agreement is explicitly amended by this Amendment, the terms of the Amendment will
control where the terms of the Agreement are contrary to or conflict with the following provisions. Where the
Development Agreement is not e